Core Insights - Ocumetics Technology Corp. is transitioning from a single Chief Medical Officer (CMO) structure to a multi-member Scientific Advisory Committee (SAC) to enhance its medical and clinical leadership as it prepares for pivotal FDA clinical trials anticipated in 2027 [2][4] - The SAC will consist of internationally recognized experts in ophthalmology, medical research, and lens science, aimed at providing diverse oversight critical for successful clinical trials and commercialization [3][4] - The company is focused on advancing its accommodating intraocular lens technology, which is designed to provide clear vision at all distances without the need for corrective lenses [6] Company Developments - The consulting agreement with the current CMO, Dr. Doyle Stulting, will terminate after a ninety-day transition period [1] - The company will announce the members of the SAC in the coming months, indicating a strategic shift in its leadership structure [4] - Dr. Stulting has significantly contributed to Ocumetics' development, and the company expresses gratitude for his service [5] Product and Technology - Ocumetics is currently in the first-in-human early feasibility study phase for its innovative intraocular lens technology [6] - The intraocular lens developed by Ocumetics is designed to fit within the natural lens compartment of the eye, potentially eliminating the need for glasses or contact lenses [6]